ChromaDex is seeking a toehold in China’s market for health supplements with its flagship anti-ageing product Tru Niagen. Photo: Handout
Nasdaq-listed ChromaDex, backed by Li Ka-shing, eyes China’s health care market with its flagship Tru Niagen anti-ageing supplement
- ChromaDex links up with Sinopharm to push Tru Niagen via e-commerce channels, plans to seek approval to sell in mainland retail stores
- China’s market for such supplements is seen surging to 27 billion yuan by 2023 from 5.1 billion yuan in 2020, iiMedia forecasts
ChromaDex is seeking a toehold in China’s market for health supplements with its flagship anti-ageing product Tru Niagen. Photo: Handout
